Older Americans Are About to Lose a Lot of Weight
New GLP‑1 weight‑loss drugs like semaglutide are raising hopes for reducing obesity and improving quality of life in older Americans, but commenters question side effects such as loss of muscle and bone mass and whether many patients will realistically adopt the resistance training needed to offset them. Others focus on the economics and regulation, debating Medicare’s projected multi‑billion‑dollar costs, patent protections, and the role of compounding pharmacies exploiting shortage rules to offer cheaper access. Running through the exchange is a deeper argument over causes of modern obesity—ultra-processed food, sedentary lifestyles, urban design, and personal responsibility—and whether medicating symptoms is acceptable while systemic diet and activity problems remain unsolved.
GLP‑1 Drugs, Aging, Muscle & Bone
- Concern that older adults on GLP‑1 drugs may regain fat after stopping but not fully regain lost muscle and bone.
- Some argue this overstates the problem: muscle can be rebuilt at any age with resistance training and high‑protein diets.
- Others reply that, in practice, older adults rarely lift weights, age‑related sarcopenia is well documented, and these drugs may worsen a problem they can “least afford.”
- Proposed compromise: prescribe exercise and resistance training alongside GLP‑1s, not as an afterthought.
Cost, Access, Patents, and Compounding
- Estimates suggest Medicare coverage for these drugs could cost billions annually; several commenters want prices driven down.
- Discussion of patent timelines and FDA “exclusivity” periods for semaglutide.
- Compounding pharmacies are reportedly sourcing semaglutide API from FDA‑licensed manufacturers under a “shortage” loophole, raising confusion about how this coexists with patents.
Discipline vs Medication
- One side: obesity is fundamentally “calories in > calories out,” so personal restraint and caloric restriction are the true solution.
- Counterpoint: long‑term weight loss is rarely sustained by “discipline” alone due to powerful biological and hormonal defenses; GLP‑1s curb appetite and can succeed where willpower fails.
- Debate over moralizing obesity vs taking a pragmatic medical approach.
Why Obesity Has Risen
- Suggested drivers: ultra‑processed foods, added sugar, cheap junk food, larger portions, higher average caloric intake, and more sedentary work and lifestyles.
- Additional factors raised: car‑centric urban design, large houses, decline in smoking, food industry lobbying and marketing, agricultural subsidies (e.g., corn), and neoliberal reluctance to address root causes.
- Minority view: causes remain unclear; hypotheses like environmental chemicals are mentioned but not resolved.
Diet vs Exercise
- Broad agreement: diet is the primary lever for weight; exercise is crucial for health and preserving muscle but rarely overcomes a high‑calorie diet.
- Dispute over how much activity matters and whether walking meaningfully increases calorie burn.
- Some emphasize that compensatory eating and metabolic adjustments blunt the impact of exercise on weight.
Children, Schools, and Long‑Term Outcomes
- Concern that school lunches and “lunch foods” are often nutritionally poor, shaping lifelong bad habits.
- Sedentary childhoods and early obesity are seen as major, under‑addressed problems.
Anecdotes and Open Questions
- Personal stories cover dramatic weight change via diet, fast food with calorie tracking, GLP‑1 use, and heavy exercise.
- One user reports substantial muscle loss on semaglutide despite prior training, then better results from long‑distance running alone.
- Overall: GLP‑1s viewed as a powerful but incomplete tool, with long‑term effects on muscle, bone, and health still seen as uncertain.